Mesoporous Silicon (PSi) for Sustained Peptide Delivery: Effect of PSi Microparticle Surface Chemistry on Peptide YY3-36 Release
- 565 Downloads
To achieve sustained peptide delivery via mesoporous silicon (PSi) microparticles and to evaluate the effects of different surface chemistries on peptide YY3-36 (PYY3-36) delivery.
PYY3-36 was loaded into thermally oxidized (TOPSi), thermally hydrocarbonized (THCPSi) and undecylenic acid treated THCPSi (UnTHCPSi) microparticles with comparable porous properties. In vitro, PYY3-36 release was investigated by centrifuge. In vivo, PYY3-36 plasma concentrations were analyzed after delivery in microparticles or solution.
Achieved loading degrees were high (12.2 – 16.0% w/w). PYY3-36 release was sustained from all microparticles; order of PYY3-36 release was TOPSi > THCPSi > UnTHCPSi both in vitro and in vivo. In mice, PSi microparticles achieved sustained PYY3-36 release over 4 days, whereas PYY3-36 solution was eliminated in 12 h. In vitro, only 27.7, 14.5 and 6.2% of loaded PYY3-36 was released from TOPSi, THCPSi and UnTHCPSi, respectively. Absolute PYY3-36 bioavailabilities were 98, 13, 9 and 38% when delivered subcutaneously in TOPSi, THCPSi, UnTHCPSi and solution, respectively. The results clearly demonstrate improved bioavailability of PYY3-36 via TOPSi and the importance of surface chemistry of PSi on peptide release.
PSi represents a promising sustained and tailorable release system for PYY3-36.
KEY WORDSin vivo mesoporous silicon peptide delivery pharmacokinetics PYY3-36
thermally hydrocarbonized porous silicon
thermally oxidized porous silicon
undecylenic acid treated thermally hydrocarbonized porous silicon
ACKNOWLEDGMENTS & DISCLOSURES
This study was financially supported by Finnish Cultural Foundation (MK), Orion Farmos Research Foundation (MK), Graduate School of Pharmaceutical Research (JM), Academy of Finland – PEPBI consortium (#117906, #118002, #217547) and the strategic funding of the University of Eastern Finland (NAMBER consortium).
- 34.A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects. ClinicalTrials.Gov. 2011 June 10. Available from: http://clinicaltrials.gov/ct2/show/NCT00537420).
- 35.Akers JM, DeFelippis RM. Peptides. In: Frokjaer S, Hovgaard L, editors. Pharmaceutical formulation development of peptides and proteins. London: CRC; 1999. p. 145–77.Google Scholar
- 45.Godin B, Gu J, Serda RE, Bhavane R, Tasciotti E, Chiappini C, et al. Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res Part A. 2010;94A:1236–43.Google Scholar
- 47.Felsovalyi F, Mangiagalli P, Bureau C, Kumar SK, Banta S (2011) Reversibility of the adsorption of lysozyme on silica. Langmuir; doi: 10.1021/la202585r.